Skip to main content
. 2023 Jul 20;228(10):1318–1325. doi: 10.1093/infdis/jiad275

Figure 3.

Figure 3.

Individual estimate of the viral clearance half-lives with point estimates (squares) and 80% credible intervals (lines). The vertical dashed lines show the median population viral clearance half-lives by treatment arm (lower: no study drug; upper: remdesivir). The median estimated viral clearance half-lives under the linear model were 12.8 (range, 4.8–50.0) hours in the remdesivir arm and 18.0 (range, 3.6–46.7) hours in the contemporaneous control arm.